Tarloxotinib bromide, also known TH-4000 or PR-610, is a prodrug designed to selectively release a covalent (irreversible) EGFR tyrosine kinase inhibitor under severe hypoxia, a feature of many solid tumors. Tarloxotinib has the potential to effectively shut down aberrant EGFR signaling in a tumor-selective manner, thus potentially avoiding or reducing the systemic side effects associated with currently available EGFR tyrosine kinase inhibitors.
MedKoo Cat#: 206511
Name: Tarloxotinib bromide
CAS#: 1636180-98-7 (bromide)
Chemical Formula: C24H24Br2ClN9O3
Exact Mass:
Molecular Weight: 681.77
Elemental Analysis: C, 42.28; H, 3.55; Br, 23.44; Cl, 5.20; N, 18.49; O, 7.04
| Solvent | mg/mL | mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 30.0 | 44.00 |
The following data is based on the product molecular weight 681.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
